Refractory neurosarcoidosis responding to infliximab.
Pettersen
J A
JA
Department of Clinical Neurosciences, University of Calgary, Foothills Hospital, Calgary, Alberta, Canada. jacqueline.pettersen@calgaryhealthregion.ca
Zochodne
D W
DW
Bell
R B
RB
Martin
L
L
Hill
M D
MD
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology; D001927:Brain Diseases / Q000188:drug therapy* / Q000473:pathology; D001929:Brain Edema / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D004351:Drug Resistance; D006099:Granuloma / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D008111:Liver Function Tests; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012507:Sarcoidosis / Q000188:drug therapy* / Q000473:pathology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab; D011241:Prednisone